pharmaphorum3d
Sanofi wins appeal in spat with NICE over Sarclisa
The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...
FiercePharma8d
J&J angles Darzalex for first move into early-stage myeloma with trial win, FDA filing
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
Zacks.com on MSN1mon
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
Following this approval, Sarclisa is the first anti-CD38 therapy in combination with VRd for treating transplant-ineligible ...
pharmaphorum1d
Sanofi's Sarclisa gets one up on rival Darzalex in myeloma
Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...
FiercePharma8d
While Novo and Lilly's market value declined in Q3, BMS, Gilead and Sanofi surged: GlobalData
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
Targeted Oncology8d
Quadruplets Seen as Top Option in Transplant-Ineligible Multiple Myeloma Due to Efficacy
Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...